Content about Analgesics

February 18, 2011

MOUNT KISCO, N.Y. — Prestige Brands became one of the first cough-cold marketers to develop a branded smart-phone app to help moms hone in on the most appropriate 
PediaCare remedy for their sick children. It’s not a bad play; a recent Millennial Media report indicated that in 2010, 32% of moms owned a smart phone, versus 20% in 2009.


February 18, 2011

NEW BRUNSWICK, N.J. — McNeil Consumer’s absence from cough-cold and analgesic aisles, including several pediatric formulations, will extend into the fourth quarter, Johnson and Johnson executives told analysts in January. 


February 18, 2011



McNeil Consumer Healthcare recently parlayed its Tylenol brand franchise into external analgesics to quite a bit of success. For the four weeks ended Dec. 26, 2010, Precise “from the makers of Tylenol” became the No. 3 best-selling heat patch, with $1.9 million in sales across food, drug and mass (excluding Walmart), according to Symphony­IRI Group. And its pain-relieving cream similarly broke in among the top-selling brands — No. 9 with $1.3 million in sales for the four-week period.

February 14, 2011

The Food and Drug Administration has accepted for review an application for a pain medication designed to thwart drug abusers.

PALATINE, Ill. — The Food and Drug Administration has accepted for review an application for a pain medication designed to thwart drug abusers.

Acura Pharmaceuticals announced Monday the acceptance of King Pharmaceuticals’ application for Acurox (oxycodone hydrochloride). King developed the drug using Acura’s Aversion technology, which is designed to limit or impede the ability to abuse the drug by dissolving or crushing the pills and then injecting them.

February 11, 2011

The Food and Drug Administration has approved a painkiller delivered through a skin patch made by Mallinckrodt, the generic drug maker said Friday.

ST. LOUIS — The Food and Drug Administration has approved a painkiller delivered through a skin patch made by Mallinckrodt, the generic drug maker said Friday.

Mallinckrodt, part of Covidien, said the FDA approved its fentanyl transdermal system patch.

The patch is a generic version of Johnson & Johnson’s Duragesic. The drug, an opioid and Class II controlled substance, is used for managing persistent, moderate-to-severe pain that requires continuous opioid administration.

February 2, 2011

GlaxoSmithKline on Wednesday announced its support for the Wounded Warrior Project and Victory Junction, a camp for children with special needs, through its analgesic powder brands, BC and Goody’s.

MEMPHIS — GlaxoSmithKline on Wednesday announced its support for the Wounded Warrior Project and Victory Junction, a camp for children with special needs, through its analgesic powder brands, BC and Goody’s.

January 27, 2011

Johnson & Johnson on Tuesday postponed its plans to begin folding many of its recalled products, including several pediatric formulations, back onto retail shelves until later this fall.

NEW BRUNSWICK, N.J. — Johnson & Johnson on Tuesday postponed its plans to begin folding many of its recalled products, including several pediatric formulations, back onto retail shelves until later this fall.

However, when those products are ready to occupy the brand blocks McNeil has carved out for Tylenol and others, J&J will be placing a significant emphasis on reacquainting those products with quality in the consumer’s mind.

January 20, 2011

British drug maker ProStrakan Group will partner with two U.S. companies to administer its risk evaluation and mitigation strategy for a cancer pain drug.

ATLANTA — British drug maker ProStrakan Group will partner with two U.S. companies to administer its risk evaluation and mitigation strategy for a cancer pain drug.

ProStrakan said it would use RelayHealth Pharmacy Solutions’ and McKesson Specialty Care Solutions’ services to administer the REMS for Abstral (fentanyl citrate), a drug that patients can place under the tongue to treat breakthrough pain associated with cancer when they already have received and become tolerant of opioid painkillers.

January 14, 2011

The Food and Drug Administration has approved a new formulation of a drug for treating acetaminophen poisoning.

NASHVILLE, Tenn. — The Food and Drug Administration has approved a new formulation of a drug for treating acetaminophen poisoning.

Cumberland Pharmaceuticals announced Thursday that the agency had approved a version of Acetadote (acetylcysteine) injection that does not contain preservatives or stabilization and chelating agents, and will replace the currently marketed version. The drug originally was approved in 2004.

January 13, 2011

The Food and Drug Administration is capping the amount of the painkiller acetaminophen in prescription drugs due to the risk of liver toxicity, the agency said Thursday.

SILVER SPRING, Md. — The Food and Drug Administration is capping the amount of the painkiller acetaminophen in prescription drugs due to the risk of liver toxicity, the agency said Thursday.

January 10, 2011

The Food and Drug Administration has approved a new drug for treating pain in cancer patients, the agency said Friday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for treating pain in cancer patients, the agency said Friday.

The FDA announced the approval of ProStrakan’s Abstral (fentanyl) transmucosal tablets for the management of pain that appears suddenly for short periods and is not alleviated by a patient’s normal pain-management plan, also known as breakthrough pain. The tablets are designed for administration on the soft surfaces of the mouth, including inside the cheek, gums and tongue, as well as the nasal passages or the throat.

January 10, 2011

The Food and Drug Administration has approved a generic drug made by Watson Pharmaceuticals for cancer-related pain, Watson said Monday.

MORRISTOWN, N.J. — The Food and Drug Administration has approved a generic drug made by Watson Pharmaceuticals for cancer-related pain, Watson said Monday.

Watson announced the approval of fentanyl buccal tablets in the 0.1-mg, 0.2-mg, 0.6-mg and 0.8-mg strengths.

December 20, 2010

Drug makers King Pharmaceuticals and Acura Pharmaceuticals have submitted a regulatory approval application to the Food and Drug Administration for an opioid pain reliever.

BRISTOL, Tenn. — Drug makers King Pharmaceuticals and Acura Pharmaceuticals have submitted a regulatory approval application to the Food and Drug Administration for an opioid pain reliever.

The two drug makers announced Tuesday the submission for Acurox (oxycodone hydrochloride), an immediate-release tablet for relief of moderate to severe pain.

The tablets use Acura’s aversion technology, designed to deter abuse of the drug by dissolving or crushing the pills.

December 15, 2010

Drug maker Watson Pharmaceuticals said it has filed a regulatory approval application for a generic painkiller, challenging the patent that covers the branded version.

MORRISTOWN, N.J. — Drug maker Watson Pharmaceuticals said it has filed a regulatory approval application for a generic painkiller, challenging the patent that covers the branded version.

Watson announced Tuesday that it had filed an application with the Food and Drug Administration seeking approval for hydromorphone hydrochloride extended-release tablets in the 8-mg, 12-mg and 16-mg strengths. The drug is a generic version of Mallinckrodt’s Exalgo.

November 24, 2010

Johnson & Johnson recalled lots of its Tylenol Cold Multi-Symptom liquid products due to insufficient labeling, the company said Wednesday.

BOSTON — Johnson & Johnson recalled lots of its Tylenol Cold Multi-Symptom liquid products due to insufficient labeling, the company said Wednesday.

The products are not being recalled due to reports of any adverse events associated with taking the product, the company added.

Earlier this week, the company recalled additional lots of millions of packages of Children's Benadryl and children's Motrin.

November 2, 2010

The value of the market for specialty injectable drugs will top $90 billion by 2014,...

October 25, 2010

Actavis last week recalled 18 lots of its patches designed to treat persistent, moderate to...

MORRISTOWN, N.J. Actavis last week recalled 18 lots of its patches designed to treat persistent, moderate to severe chronic pain.

October 24, 2010

There is a pair of significant reasons sales of external analgesics, including heat and ice...

October 24, 2010

Community pharmacists got a briefing about pharmacy security from a company that has learned a...

October 24, 2010

According to a recent study released by the Relational Capital Group, consumer purchase intent and...

PHILADELPHIA —According to a recent study released by the Relational Capital Group, consumer purchase intent and brand loyalty for Tylenol still is high despite the recent spate of Tylenol product recalls. According to the study, 76% of consumers reported positive purchase intent, and 67% reported positive brand loyalty for Tylenol.

October 18, 2010

McNeil Consumer Healthcare has pulled a lot of Tylenol off the market, following complaints of...

FORT WASHINGTON, Pa. McNeil Consumer Healthcare has pulled a lot of Tylenol off the market, following complaints of a musty odor.

McNeil said the uncharacteristic odor is thought to be caused by the presence of trace amounts of a chemical called 2,4,6-tribromoanisole. The lot of Tylenol 8-Hour, 50-count bottles are part of lot number BCM155 and carry the following UPC code: 3 0045-0297-51 8.

October 18, 2010

Drug maker Purdue Pharma has donated $200,000 to the National Association of State Controlled Substances...

CHARLESTON, S.C. Drug maker Purdue Pharma has donated $200,000 to the National Association of State Controlled Substances Authorities to address the abuse of prescription drugs, NASCSA said Tuesday.

 

The grant, presented at the group’s annual conference in Charleston, S.C., is designed to support state prescription drug monitoring programs. The NASCSA will be in charge of distributing the money to state agencies. Purdue is the maker of OxyContin (oxycodone), a commonly abused prescription opioid painkiller.

 

 

October 12, 2010

The Food and Drug Administration approved a drug to treat and prevent relapse after patients...

SILVER SPRING, Md. The Food and Drug Administration approved a drug to treat and prevent relapse after patients with opioid dependence have undergone detoxification treatment.

Vivitrol is an extended-release formulation of naltrexone -- which works to block opioid receptors in the brain -- administered by intramuscular injection once a month. It only is administered by a physician.

 

October 11, 2010

McNeil Consumer Healthcare recently parlayed its Tylenol brand franchise into external analgesics....

NEW YORK McNeil Consumer Healthcare recently parlayed its Tylenol brand franchise into external analgesics.

October 10, 2010

While the fact that two Food and Drug Administration advisory committees collectively voted 15 opposed...